Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

ASTRAZENECA PHARMA INDIA LTD.

NSE : ASTRAZENBSE : 506820ISIN CODE : INE203A01020Industry : Pharmaceuticals & DrugsHouse : Astrazeneca Pharma India - MNC

BSE7441.40213.9 (+2.96 %)

PREV CLOSE ( ) 7227.50

OPEN PRICE ( ) 7242.35

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 1525

TODAY'S LOW / HIGH ( )7091.90 7550.30

52 WK LOW / HIGH ( )4050.15 8139.85

NSE7410.30175.2 (+2.42 %)

PREV CLOSE( ) 7235.10

OPEN PRICE ( ) 7235.10

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 7410.30 (135)

VOLUME 21729

TODAY'S LOW / HIGH( ) 7057.00 7545.00

52 WK LOW / HIGH ( )4785 8139

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 11-07 1979

Management Info

Shilpa Divekar Nirula - Chairman Sanjeev Kumar Panchal - Managing Director

Registered Office

Address Block N1, 12th Floor,Manyata Embassy Business Park,Rachenahalli, Outer Ring Road,
Bengaluru,
Karnataka-560045

Phone 080 6774 8000

Email comp.secy@astrazeneca.com

Website www.astrazenecaindia.com/india

Registrars Details

Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd)

30, Ramana Residency,4th Cross, Sampige Road,Malleswaram,Bangalore

Listing : BSE, NSE

NEWS

12Dec Astrazeneca Pharma India informs about
Astrazeneca Pharma India has informed that, in accordance with the provi..

12Dec Astrazeneca Pharma India informs about
Astrazeneca Pharma India has informed that in accordance with the provis..

09Dec Astrazeneca Pharma India informs about
Astrazeneca Pharma India has informed that it enclosed certificate dated..

04Dec AstraZeneca Pharma India informs about
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..

19Nov AstraZeneca Pharma to launch Breztri A
AstraZeneca Pharma India is all set to launch Budesonide Ph. Eur 160mcg+..

Financials

Rs. in Millions

	QTR Sep 24	ANNUAL 24
Net Profit	384.300000000001	1615.09
Gross Profit	510.300000000001	2195.37
Operating Profit	606.900000000001	2192.52
Net Sales	4080	12955.28

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Wockhardt (BSE) 1557.15 (10.00%)	M.Cap ( in Cr)25299.38
Medplus Health Servi (BSE) 787.20 (8.64%)	M.Cap ( in Cr)9422.30
Suven Pharma (BSE) 1108.25 (4.99%)	M.Cap ( in Cr)28212.16
Bajaj Healthcare (BSE) 690.80 (8.20%)	M.Cap ( in Cr)2181.77
Divi's Lab (BSE) 5622.30 (0.83%)	M.Cap ( in Cr)149254.40

Shareholding Pattern

	PROMOTERS	75%
	NON-INSTITUTION	16.87%
	MUTUAL FUNDS/UTI	5.04%
	FI/BANKS/INSURANCE	0.13%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Bandhan Innovation ...	3.33
Baroda BNP Paribas ...	1.82
ICICI Pru Pharma He...	1.77
Bandhan Hybrid Equi...	1.47
ICICI Pru Smallcap ...	1.10
ICICI Pru Innovatio...	1.06
Nippon India Small ...	0.78

Risk Disclosures on Derivatives

Smart Quotes

ASTRAZENECA PHARMA INDIA LTD.